Hims & Hers Health, Inc. (NYSE:HIMS) shares rose more than 19% since the company’s reported Q4 results on Monday, with EPS of ($0.05) coming in better than the Street estimate of ($0.06). Revenue was $167.2 million, beating the Street estimate of $160.8 million.
The company expects Q1/23 revenue to be in the range of $175-180 million, better than the Street estimate of $163 million. For the full year, the company expects revenue to be in the range of $735-755 million, above the Street estimate of $727 million.
The company provided its 2025 expectations, calling for revenue of at least $1.2 billion and adjusted EBITDA of at least $100 million, both figures trending ahead of the Street estimates. The revenue outlook is consistent with management’s prior commentary of at least a 30% growth rate in the next several years.
At CWEB, we are always looking to expand our network of strategic investors and partners. If you're interested in exploring investment opportunities or discussing potential partnerships and serious inquiries. Contact: jacque@cweb.com